Treats Major Depressive Disorder. ANDA 78572, held by Dr Reddys Labs Ltd. Fluoxetine Hydrochloride.
As of Nov 16, 2026, ANDA 78572 (Fluoxetine Hydrochloride), held by Dr Reddys Labs Ltd, was first approved by FDA on Mar 22, 2010, with 10 approved supplements and 0 published complete response letters.
Fluoxetine delayed-release capsules are indicated for the treatment of:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 22, 2010 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Fluoxetine HydrochlorideEQ 90MG BASE · capsule, delayed rel pellets;oral | Fluoxetine Hydrochloride | Rx |
| Aug 18, 2023 | Supplement 13Labeling · Standard review | Approved | None posted |
| Sep 20, 2021 | Supplement 11Labeling · Standard review | Approved | None posted |
| Sep 1, 2021 | Supplement 9Labeling · Standard review | Approved | None posted |
| Sep 1, 2021 | Supplement 8Labeling · Standard review | Approved | None posted |
| Sep 1, 2021 | Supplement 7Labeling · Standard review | Approved | None posted |
| Nov 3, 2014 | Supplement 6Labeling · Standard review | Approved | None posted |
| Nov 3, 2014 | Supplement 5Labeling · Standard review | Approved | None posted |
| Nov 3, 2014 | Supplement 4Labeling · Standard review | Approved | None posted |
| Feb 28, 2012 | Supplement 3Labeling | Approved | None posted |
| Nov 22, 2011 | Supplement 2Labeling | Approved | None posted |
| Mar 22, 2010 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters